Patent application number | Description | Published |
20090117615 | Recombinant mammal cells, method of producing thereof, and method of producing proteins of interest - The present invention relates to a method of expressing an objective protein at a high level and stably as well as for a long period even in the absence of a selection drug with a recombinant mammal cell. More particularly, the present invention relates to a method of producing an objective protein by providing a recombinant mammal cell having multiple copies of the exogenous objective protein gene expression unit integrated into a hypoxanthine-phosphoribosyl transferase enzyme (hprt) gene locus and culturing said cell. | 05-07-2009 |
20110014245 | THERAPEUTIC METHOD OF ADMINISTERING PHARMACEUTICAL TITANIUM DIOXIDE COMPOSITE AND LIGHT IRRADIATION - A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required. | 01-20-2011 |
20110060269 | METHOD FOR KILLING CELLS USING PHOTOCATALYTIC TITANIUM DIOXIDE PARTICLES - Photocatalytic titanium dioxide particles are disclosed having improved dispersibility into an aqueous solvent not only under neutral physiological conditions in vivo but also over a wide pH range, and improved cell affinity and cell uptake property. The photocatalytic titanium dioxide particles comprise particles comprising photocatalytic titanium dioxide and a cationic hydrophilic polymer modifying surfaces of the photocatalytic titanium dioxide particles, wherein the hydrophilic polymer is bonded to the photocatalytic titanium dioxide particles. The particles are very useful for medical applications, such as destruction of cancer cells, e.g., when administered to a mammal the titanium dioxide particles are taken up by cells of the mammal, and if then irradiated with UV light the particles kill the cells via photocatalytic degrading capability. | 03-10-2011 |
Patent application number | Description | Published |
20080261805 | Photocatalytic Titanium Dioxide Microparticle, Dispersion Liquid Thereof and Process for Producing the Same - Photocatalytic titanium dioxide particles are disclosed having improved dispersibility into an aqueous solvent not only under neutral physiological conditions in vivo but also over a wide pH range, and improved cell affinity and cell uptake property. The photocatalytic titanium dioxide particles comprise particles comprising photocatalytic titanium dioxide and a cationic hydrophilic polymer modifying surfaces of the photocatalytic titanium dioxide particles, wherein the hydrophilic polymer is bonded to the photocatalytic titanium dioxide particles. The photocatalytic titanium dioxide particles are very useful for medical applications, such as destruction of cancer cells. | 10-23-2008 |
20080262349 | Ultrasonic Cancer Treatment Enhancer and Cell Killer - There is provided an ultrasonic cancer treatment enhancer and cell killer that can significantly improve the effect of treating cancer by ultrasonic irradiation while ensuring a high level of safety. The ultrasonic cancer treatment enhancer and cell killer comprise metal semiconductor particles and can be activated upon ultrasonic irradiation to kill or destruct cancer cells. | 10-23-2008 |
20090297620 | Anti-Tumor Agent - Titanium oxide-antibody conjugated particles are disclosed, which are provided with selective binding ability without loss of dispersibility and catalytic activity by modifying titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, with an antibody via a linker molecule bound without changing the nature of the water-soluble polymer. The present invention is an antitumor agent, comprising titanium oxide-antibody conjugated particles, wherein a linker molecule is bound to the titanium oxide surface of the titanium oxide conjugated particles, dispersed in a water-based solvent by a water-soluble polymer, via at least one functional group selected from a group consisting of a carboxyl group, an amino group, a diol group, a salicylic acid group, and a phosphoric acid group, and wherein the titanium oxide conjugated particles are further modified with an antibody via the linker molecule. This antitumor agent is concentrated in the affected area and can be utilized as an agent for diagnosis or for treatment in combination with ultrasonic irradiation. | 12-03-2009 |
20100136115 | Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation - Disclosed is a titanium dioxide composite material which can be dispersed in an aqueous solvent stably and can be administered to a living body in a simple manner and in which the pharmacological effect of a therapeutic compound carried on the composite material can be eliminated by irradiation with light. Also disclosed is a dispersion product of the composite material. The composite material comprises titanium dioxide which has a photocatalytic activity and a therapeutic compound attached to the titanium dioxide through a hydrophilic polymer. The composite material is stable in an aqueous solvent and can be administered to a living body in a simple manner. After the composite material is administered to a living body, a site on the living body where the pharmacological effect of the therapeutic compound is not needed to be developed can be irradiated with light to induce the light excitation of titanium dioxide at the site, thereby decomposing the therapeutic compound to reduce any adverse side effect of the therapeutic compound. | 06-03-2010 |